Condensate Therapeutics for Infectious Diseases

CD BioSciences is dedicated to developing disease-targeted condensate therapeutics to advance the field of refractory diseases. Here, we offer condensate therapeutics for infectious diseases, offering new hope for the treatment of viral infections.

Condensate Research Offers New Hope for the Treatment of Viral Infections

Viruses are essential intracellular parasites that are highly dependent on the mechanisms of the hosts they infect. Studies have shown that many viruses, including influenza, HIV, rabies, measles, and the viruses causing COVID-19, SARS-CoV-2, use biomolecular condensates to propagate in cells. to mediate viral replication and nucleocapsid assembly and thus propagate in the cell. The role of biomolecular cohesions has now been linked to multiple steps in the viral replication cycle, including virus entry and exit, transcription, protein synthesis, and genome and viral particle assembly. Changing the physical state of biomolecular condensates to one that impedes the ability of viruses to multiply may be an innovative approach to treating viruses, especially when they become resistant to antiviral therapy.

Fig. 1. Working model for the strategies to modulate influenza A virus (IAV) liquid inclusions. (Etibor TA, et al, 2023)

Our Solutions

CD BioSciences offers comprehensive services to analyze biomolecular condensates associated with a wide range of viral infections with aimed to develop new therapeutic targets for the treatment of viral infections. Our multidisciplinary team of virologists, biophysicists, and drug development experts is dedicated to unraveling the mechanisms and properties of viral condensates and translating this knowledge into effective therapeutic strategies.

CD BioSciences is committed to developing novel antiviral therapies targeting viral biomolecular condensates. Our solutions include:

• Small Molecules as Modulators
  Our experts design and develop small molecules to modulate the material properties and functions of viral condensates to inhibit viral replication and pathogenesis. We design chemical probes that lyse viral condensates by interacting with viral proteins involved in phase separation. In addition, we develop synthetic peptides that target specific structural domains within viral condensates.
• Engineering Condensates Hardeners
  Our experts are also working on the development of condensates-hardening drugs. Such drugs are capable of inducing a liquid-to-solid phase transition of viral inclusion bodies, where we can impair their mobility and restrict the movement of viral components, thereby impeding viral replication and assembly. This approach has the potential to be used as a broad-spectrum antiviral strategy.
• Engineering Synthetic Condensates
  By designing and controlling the composition and physical properties of synthetic condensates, we can create targeted platforms for studying viral replication and testing therapeutic interventions. We aim to develop synthetic condensates for you to use in high-throughput screening of antiviral compounds.
• Combination Therapy
  By strategically combining small molecule inhibitors, synthetic peptides, and other antiviral agents, we can improve patient outcomes by increasing the efficacy of therapy and reducing the emergence of viral escape mutants.

CD BioSciences leverages its expertise in condensate biology, drug discovery, and interdisciplinary collaborations to advance the development of innovative and effective antiviral therapies targeting viral biomolecular condensates. Our goal is to advance the development of treatments for viral infections. If you are interested in our solutions, please contact us for more information.